BioCentury | Nov 15, 2019
Company News

Roche adds to fibrosis portfolio with $390M Promedior acquisition

...The biotech had raised $72.5 million across five venture financings from a syndicate that included Easton Capital...
BioCentury | Nov 5, 2012
Financial News

Resolve Therapeutics completes venture financing

...Date completed: 11/1/12 Type: Venture financing Raised: $5.8 million Investors: New Science Ventures; WRF Capital; Easton Capital WIR...
BioCentury | Mar 12, 2012
Financial News

Promedior completes venture financing

...$21.5 million Investors: Fibrotec Ventures; Morgenthaler Ventures; HealthCare Ventures; Polaris Venture Partners; Forbion Capital Partners; Easton Capital...
BioCentury | Mar 8, 2012
Financial News

Promedior raises $21.5 million in series D

...existing investors participated, including Morgenthaler Ventures; HealthCare Ventures; Polaris Venture Partners; Forbion Capital Partners; and Easton Capital...
BioCentury | Jul 25, 2011
Emerging Company Profile

Resolve: Early answers, early exits

...partners: None Number of employees: 10 Funds raised: $2 million Investors: New Science Ventures and Easton Capital...
BioCentury | May 23, 2011
Financial News

Resolve Therapeutics completes venture financing

...Business: Autoimmune Date completed: 5/17/11 Type: Venture financing Raised: $2 million Investors: New Science Ventures; Easton Capital...
BioCentury | Apr 25, 2011
Financial News

bluebird bio completes venture financing

...Raised: $30 million Investors: Arch Venture Partners; Third Rock Ventures; TVM Capital; Forbion Capital Partners; Easton Capital...
BioCentury | Apr 25, 2011
Finance

Third Deal on the Run

...$35 million B round. The firm joined existing investors TVM Capital, Forbion Capital Partners and Easton Capital...
BioCentury | Apr 21, 2011
Financial News

bluebird raises $30 million

...Arch Venture Partners joined existing investors Third Rock Ventures; TVM Capital; Forbion Capital Partners; and Easton Capital...
BioCentury | Apr 5, 2010
Finance

Easton's "OAD" Model

Easton Capital is raising a pair of life sciences funds. One will be a classic 10-year fund targeted to raise $100-$200 million for biotech investment. The other will aim for $50-$75 million for investment in...
Items per page:
1 - 10 of 22
BioCentury | Nov 15, 2019
Company News

Roche adds to fibrosis portfolio with $390M Promedior acquisition

...The biotech had raised $72.5 million across five venture financings from a syndicate that included Easton Capital...
BioCentury | Nov 5, 2012
Financial News

Resolve Therapeutics completes venture financing

...Date completed: 11/1/12 Type: Venture financing Raised: $5.8 million Investors: New Science Ventures; WRF Capital; Easton Capital WIR...
BioCentury | Mar 12, 2012
Financial News

Promedior completes venture financing

...$21.5 million Investors: Fibrotec Ventures; Morgenthaler Ventures; HealthCare Ventures; Polaris Venture Partners; Forbion Capital Partners; Easton Capital...
BioCentury | Mar 8, 2012
Financial News

Promedior raises $21.5 million in series D

...existing investors participated, including Morgenthaler Ventures; HealthCare Ventures; Polaris Venture Partners; Forbion Capital Partners; and Easton Capital...
BioCentury | Jul 25, 2011
Emerging Company Profile

Resolve: Early answers, early exits

...partners: None Number of employees: 10 Funds raised: $2 million Investors: New Science Ventures and Easton Capital...
BioCentury | May 23, 2011
Financial News

Resolve Therapeutics completes venture financing

...Business: Autoimmune Date completed: 5/17/11 Type: Venture financing Raised: $2 million Investors: New Science Ventures; Easton Capital...
BioCentury | Apr 25, 2011
Financial News

bluebird bio completes venture financing

...Raised: $30 million Investors: Arch Venture Partners; Third Rock Ventures; TVM Capital; Forbion Capital Partners; Easton Capital...
BioCentury | Apr 25, 2011
Finance

Third Deal on the Run

...$35 million B round. The firm joined existing investors TVM Capital, Forbion Capital Partners and Easton Capital...
BioCentury | Apr 21, 2011
Financial News

bluebird raises $30 million

...Arch Venture Partners joined existing investors Third Rock Ventures; TVM Capital; Forbion Capital Partners; and Easton Capital...
BioCentury | Apr 5, 2010
Finance

Easton's "OAD" Model

Easton Capital is raising a pair of life sciences funds. One will be a classic 10-year fund targeted to raise $100-$200 million for biotech investment. The other will aim for $50-$75 million for investment in...
Items per page:
1 - 10 of 22